From anti-fungal to potential neurotherapeutic: Posaconazole as an effective inhibitor of cellular TDP-43 pathology
Noah Nathan Kochen, Sophia Zafari, Aimee Renaud, Nathan Schneider, Nagamani Vunnam, Elly E. Liao, James R. Dutton, Anthony R. Braun, Jonathan N. Sachs
This study identifies posaconazole as a more effective and safer alternative to ketoconazole for inhibiting TDP-43 pathology in ALS/FTD by reducing aggregation and restoring SREBP2 levels.
bioRxiv · Jun 4, 2026 · PreprintCell Biology